Advertisement
Letter to the Editor| Volume 86, ISSUE 1, P66-117, January 2023

Download started.

Ok

In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Pseudomonas aeruginosa in Taiwan: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) in 2020

  • Yuag-Meng Liu
    Affiliations
    Department of Internal Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan

    Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
    Search for articles by this author
  • Wen-Chien Ko
    Affiliations
    Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    Search for articles by this author
  • Mao-Wang Ho
    Affiliations
    Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
    Search for articles by this author
  • Yu-Lin Lee
    Affiliations
    Department of Internal Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan

    Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
    Search for articles by this author
  • Po-Ren Hsueh
    Correspondence
    Corresponding author at: Department of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan.
    Affiliations
    Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan

    Department of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan

    School of Medicine, China Medical University, Taichung, Taiwan

    Ph.D. Program in Ageing, School of Medicine, China Medical University, Taichung, Taiwan
    Search for articles by this author
Published:November 02, 2022DOI:https://doi.org/10.1016/j.jinf.2022.10.038
In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Pseudomonas aeruginosa in Taiwan: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) in 2020
Previous ArticleMultidrug-resistant infection in COVID-19 patients: A meta-analysis
Next ArticleRegdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
      Dear Editor,
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • La Y.
        • Hong J.Y.
        • Lee H.S.
        • Lee E.H.
        • Lee K.H.
        • Song Y.G.
        • et al.
        Increase of multidrug-resistant bacteria after the COVID-19 pandemic in South Korea: time-series analyses of a long-term multicenter cohort.
        J Infect. 2022; (Sep 29:S0163-4453(22)00556-4)
        View in Article
        • Liu Y.M.
        • Chen Y.S.
        • Toh H.S.
        • Huang C.C.
        • Lee Y.L.
        • Ho C.M.
        • et al.
        In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
        Int J Antimicrob Agents. 2012; 40 (Suppl): S11-S17
        View in Article
        • Bassetti M.
        • Vena A.
        • Croxatto A.
        • Righi E.
        • Guery B.
        How to manage Pseudomonas aeruginosa infections.
        Drugs Context. 2018; 7212527
        View in Article
        • Moyá B.
        • Beceiro A.
        • Cabot G.
        • Juan C.
        • Zamorano L.
        • Alberti S.
        • et al.
        Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.
        Antimicrob Agents Chemother. 2012; 56: 4771-4778
        View in Article
        • Feng W.
        • Huang Q.
        • Wang Y.
        • Yuan Q.
        • Li X.
        • Xia P.
        • et al.
        Changes in the resistance and epidemiological characteristics of Pseudomonas aeruginosa during a ten-year period.
        J Microbiol Immunol Infect. 2021; 54: 261-266
        View in Article
        • Hsueh P.R.
        Study for Monitoring Antimicrobial Resistance Trends (SMART) in the Asia-Pacific region, 2002-2010.
        Int J Antimicrob Agents. 2012; 40 (Suppl): S1-S3
        View in Article
        • Lee Y.L.
        • Lu M.C.
        • Shao P.L.
        • Lu P.L.
        • Chen Y.H.
        • Cheng S.H.
        • et al.
        Nationwide surveillance of antimicrobial resistance among clinically important Gram-negative bacteria, with an emphasis on carbapenems and colistin: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2018.
        Int J Antimicrob Agents. 2019; 54: 318-328
        View in Article
        • Jean S.S.
        • Lu M.C.
        • Ho M.W.
        • Ko W.C.
        • Hsueh P.R.
        Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019.
        J Microbiol Immunol Infect. 2022; 59106521
        View in Article
        • Teo J.Q.
        • Tang C.Y.
        • Lim J.C.
        • Lee S.J.
        • Tan S.H.
        • Koh T.H.
        • et al.
        Genomic characterization of carbapenem-non-susceptible Pseudomonas aeruginosa in Singapore.
        Emerg Microbes Infect. 2021; 10: 1706-1716
        View in Article
        • Lob S.H.
        • Hoban D.J.
        • Young K.
        • Motyl M.R.
        • Sahm D.F.
        Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata - SMART United States 2016-2017.
        J Glob Antimicrob Resist. 2020; 20: 209
        View in Article

      Article info

      Publication history

      Published online: November 02, 2022
      Accepted: October 30, 2022

      Identification

      DOI: https://doi.org/10.1016/j.jinf.2022.10.038

      Copyright

      © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX